Diabetes, Metabolic Syndrome and COVID-19 patients.

Diabetes, Metabolic Syndrome and COVID-19 patients.

This is an initiative by Medtalks, in association with Mankind Pharma. Through this news bulletin, we aim to bring to you everything that is new in the field of diabetes care from across the world

In this issue we will discuss about Diabetes, Metabolic syndrome and COVID-19 patients.

According to a new study patients hospitalized with COVID-19 who had a combination of high blood pressure, obesity and diabetes were over three times more likely to die from the disease.

The study, published in the journal Diabetes Care, is the first to look at the impact of metabolic syndrome on outcomes for COVID-19 patients.

Dr. Shashank Joshi

MBBS, MD, DM, FACP, FRCP, FACE, An Indian endocrinologist, diabetologist and medical researcher. He was honoured by the Government of India, in 2014, by bestowing on him the Padma Shri, the fourth highest civilian award, for his services to the field of medicine. Graduated from Grant Medical College & Sir JJ Group of Hospitals (MBBS) and did residency in Internal Medicine (MD) with Gold Medals and First Rank for excellence. A Fellow of the Royal College of Physicians, as well as a Fellow of the Indian College of Physicians (FICP) and American College of Physicians (FACP). A Fellow of the American College of Endocrinology (FACE) and the Chair of AACE Indian Chapter. Affiliated to several leading hospitals of the city including Lilavati and Bhatia Hospitals. Faculty, Department of Endocrinology, Seth G.S. Medical College and KEM Hospital, Mumbai. Visiting faculty to several Indian and International Universities and is actively involved with evidence based work in Endocrinology including Obesity, Diabetes, Growth, Thyroid, and Osteoporosis.

 More FAQs by Dr. Shashank Joshi